ITC investigates online pharmacies after Eli Lilly complaint
International Trade Commission is to investigate 11 online pharmacies after Eli Lilly files trademark infringement complaint | The company accuses pharmacies of selling “low-grade” versions of its Mounjaro diabetes medicine.
Eli Lilly has filed a complaint at the US International Trade Commission (ITC) for trademark infringement and safety concerns against 11 online pharmacies that are allegedly selling “low-grade” versions of its Mounjaro medicine.
This complaint has led the ITC to launch an investigation into certain products containing tirzepatide, the active ingredient in Mounjaro, used to treat Type 2 diabetes in adults.
Eli Lilly claims that the online pharmacies are selling or distributing unauthorised versions of the treatment, which is administered through once-weekly injections.
The pharmaceutical giant is seeking the issuance of a general exclusion order and cease-and-desist orders against those selling allegedly infringing and unlawfully advertised unapproved drug products containing tirzepatide.
The online pharmacies have been accused of misusing Lilly’s trademark and making false and misleading statements regarding the approval and association of the product.
Lilly claimed this has caused harm to unknowing consumers, as these are being sold without a prescription and are not tested for safety and sterility.
This comes a month after Lilly filed lawsuits against eight companies for producing or selling lower-quality versions of Mounjaro.
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.
